Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
p53
expression is strongly modulated during the process of induced differentiation, at the same time as both cell cycle and genetic expression become modulated, giving rise to a commitment to terminal differentiation. We took advantage of two murine cell lines inducible for differentiation, an
erythroleukemia
and a melanoma cell line, to outline common features of the regulation of
p53
expression during the differentiation process. We found that
p53 mRNA
decreased early after induced differentiation and that regulation was controlled at a posttranscriptional level. Our data showed that this regulation affects
p53
pre-mRNA maturation. Because, in both systems used, actinomycin D treatment abolished the inducer-mediated decrease of
p53 mRNA
, we looked for induced RNAs potentially involved in this process. Using different parts of the
p53
gene and flanking regions as probes, we identified three RNA species whose expression is modulated during induced differentiation. A first species is made of high molecular weight RNAs that accumulate in the nuclear compartment and seem to represent antisense transcripts of the
p53
gene. A second species, 1.3-kb long, was found to accumulate in the nucleus of induced MEL cells and was homologous to a restricted part of the first intron of the
p53
gene due to the presence of a B1 repetitive element in an antisense orientation with respect to the
p53
pre-messenger RNA. Finally, a family of B2-containing RNAs was observed in both cytoplasmic and nuclear compartments. The variation in the amounts of sense and antisense RNAs, respectively, suggested an interesting speculative model for the maturation of B2-containing pre-messenger RNAs.
...
PMID:Antisense RNA and p53 regulation in induced murine cell differentiation. 134 Jan 59
A point mutation at codon 129 of the murine erythropoietin receptor (cEpoR) results in constitutive activation. We have generated a recombinant spleen focus-forming retrovirus in which the env gene is replaced by the cEpoR cDNA. Mice infected with this virus (but not by viruses expressing the wild-type EpoR) develop erythrocytosis and splenomegaly. From the spleen of infected animals we have isolated clonal, growth factor-independent, proerythroblast cell lines that express cEpoR, do not express the putative oncogene spi-1, and have rearranged and inactivated expression of the
p53
suppressor oncogene. These cells induce
erythroleukemia
upon injection into mice. This demonstrates that oncogenic point mutations exist in a member of the cytokine receptor superfamily. The activated erythropoietin receptor does not transform cultured fibroblasts, suggesting why oncogenic mutations in other members of this receptor superfamily have not been detected.
...
PMID:An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. 166 16
The Friend
erythroleukemia
virus complex contains no cell-derived oncogene. Transformation by this virus may therefore involve mutations affecting cellular gene expression. We provide evidence that inactivating mutations of the cellular
p53
gene are a common feature in Friend virus-induced malignancy, consistent with an antioncogene role for
p53
in this disease. We have shown that frequent rearrangements of the
p53
gene cause loss of expression or synthesis of truncated proteins, whereas overexpression of
p53 protein
is seen in other Friend cell lines. We now demonstrate that
p53
expression in the latter cells is also abnormal, as a result of missense mutations in regions encoding highly conserved amino acids. Three of these aberrant alleles obtained from cells from different mice were cloned and found to function as dominant oncogenes in gene transfer assays, supporting the view that certain naturally occurring missense mutations in
p53
confer a dominant negative phenotype on the encoded protein.
...
PMID:Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. 169 8
Mutations in the
p53
tumor-suppressor gene have been implicated in the pathogenesis of a significant proportion of human cancers and in a dominantly inherited familial cancer syndrome (
Li-Fraumeni syndrome)
. Frequent rearrangements and point mutations have also been detected in the
p53
gene in the murine erythroleukemias induced by Friend leukemia virus. We have previously reported that transgenic mice overproducing a mutated
p53 protein
are predisposed to the development of lung carcinomas, bone and soft-tissue sarcomas, as well as lymphoid malignancies. Here we report that
p53
transgenic mice infected with the polycythemia-inducing strain of Friend virus (FV-P) progress to the late stage of
erythroleukemia
more rapidly than do normal mice. In addition, Friend leukemic cell lines derived from
p53
transgenic mice overproduce mutant p53 protein and show a high frequency of rearrangement of the ets-related Spi-1 oncogene, as previously reported in Friend cell lines derived from non-transgenic animals. These results suggest that the same genetic changes involved in the evolution of Friend leukemia in normal mice are also required in mice with an inherited predisposition to cancer. The data also indicate that
p53
transgenic mice provide an animal model in which to analyse the role that genetic and environmental factors play in influencing cancer predisposition.
...
PMID:p53 transgenic mice: accelerated erythroleukemia induction by Friend virus. 176 68
Inactivation of the cellular
p53
gene is a common feature of Friend virus-induced murine
erythroleukemia
cell lines and may represent a necessary step in the progression of this disease. As well, frequent loss or mutation of
p53
alleles in diverse human tumors is consistent with the view of
p53
as a tumor suppressor gene. To examine the significance of
p53
gene inactivation in tumorigenesis, we have attempted to express transfected wild-type
p53
in three
p53
-negative tumor cell lines: murine DP16-1 Friend
erythroleukemia
cells, human K562 cells, and SKOV-3 cells. We found that aberrant
p53
proteins, which differ from wild-type
p53
by a single amino acid substitution, were expressed stably in these cells, whereas wild-type
p53
expression was not tolerated. The inability of
p53
-negative tumor cell lines to support long-term expression of wild-type
p53 protein
is consistent with the view that
p53
is a tumor suppressor gene.
...
PMID:Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. 198 14
We identified a B2 repetitive element approximately 1.9kb down stream from mouse
p53
coding gene. This element was then used as a probe to investigate the expression of B2 containing RNA during the induced differentiation of murine
erythroleukemia
(MEL) cells. This probe revealed two nuclear and one cytoplasmic RNA species. Nuclear small RNAs had a biphasic variation: a decrease followed by a reaccumulation. The cytoplasmic species was essentially non polysomal, and disappeared after the induced differentiation. The presented results suggest that the regulation of these RNAs is associated to cell proliferation and differentiation respectively.
...
PMID:Modulation of B2 containing small RNAs during induced differentiation of murine erythroleukemia cells. 199 22
A group of retroviruses carrying truncated viral genes has recently been suggested as the cause of new patterns of diseases. One such virus is the replication defective component of the Friend murine leukemia virus (F-MuLV) complex, called Friend spleen focus forming virus (F-SFFV). This virus induces erythroblastosis, and a virion envelope-related glycoprotein, gp55, encoded by F-SFFV has been suggested as the pathogenic gene. The role of the gp55 gene is, however, yet unclear in the apparently multistep erythroleukemogenesis. By separately producing transgenic mice harboring the whole F-SFFV DNA, the gp55 gene alone under the control of the retroviral long terminal repeat (LTR) and the gp55 gene under the control of cytoplasmic beta actin transcriptional regulatory unit, we show here that the gp55 gene is capable of inducing neoplastic proliferation of erythroid progenitor cells specifically in the absence of helper virus and other F-SFFV sequences. Under the control of the viral LTR the gp55 expression was detected only in leukemic tissues, but under the control of cytoplasmic beta-actin regulatory sequences, the gp55 was also expressed in a variety of normal tissues including preleukemic normal spleens. The development of
erythroleukemia
was suppressed under the genetic background of C57B1/6 mouse (resistant to F-MuLV; Fv-2rr), and required additional events even under the background of DDD mouse (susceptible to F-MuLV; Fv-2ss). The
p53
and Spi-1 genes were frequently aberrant in transplanted tumors and cell lines derived from them, but were not in primary leukemic spleens.
...
PMID:Env-derived gp55 gene of Friend spleen focus-forming virus specifically induces neoplastic proliferation of erythroid progenitor cells. 216 63
The proto-oncogenes myc, myb, and
p53
produce nuclear proteins which have been implicated in the regulation of proliferation or differentiation in a number of systems. The expression of these proto-oncogenes was studied in murine
erythroleukemia
(MEL) cells during (i) normal replication, (ii) DMSO-induced differentiation and (iii), alpha-difluoromethylornithine (DFMO)-restricted cell division and differentiation. The RNA levels of c-myc, c-myb, and
p53
were all elevated during normal cellular proliferation; only c-myc expression declined when the cells stopped dividing although the rate of transcription for the gene was unaltered. In contrast, treatment of the cells with DFMO resulted in gradual cessation of cell replication and a decrease in transcription of c-myc, c-myb and
p53
. When the MEL cells were induced to differentiate with dimethyl sulfoxide (DMSO), a transient reduction in c-myc and c-myb RNA levels occurred immediately prior to the G1 arrest with a concomitant decrease in transcriptional activity, while
p53 mRNA
production was elevated without an increase in transcription. Similar changes of the proto-oncogene levels were observed when the MEL cells were incubated with DFMO and then later induced with DMSO, a protocol which restricts differentiation of the MEL cells. From these experiments we conclude that (i) c-myc, c-myb, and
p53
are regulated independently at both the transcriptional and post-transcriptional levels, (ii) DFMO inhibits MEL cell proliferation and expression of several genes, including c-myc, c-myb and
p53
, and (iii) DFMO suppresses terminal differentiation but is unable to alter proto-oncogene changes associated with the early stages of differentiation.
...
PMID:Transcriptional and post-transcriptional regulation of c-myc, c-myb, and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO. 245 48
We have investigated the role of the
p53
gene in oncogenesis in vivo by generating transgenic mice carrying murine
p53
genomic fragments isolated from a mouse Friend
erythroleukemia
cell line or BALB/c mouse liver DNA. Elevated levels of
p53 mRNA
were detected in several tissues of two transgenic lines tested. Increased levels of
p53 protein
were also detected in most of the tissues analyzed by Western blotting (immunoblotting). Because both transgenes encoded
p53
proteins that were antigenically distinct from wild-type
p53
, it was possible to demonstrate that overexpression of the
p53 protein
was mostly, if not entirely, due to the expression of the transgenes. Neoplasms developed in 20% of the transgenic mice, with a high incidence of lung adenocarcinomas, osteosarcomas, and lymphomas. Tissues such as ovaries that expressed the transgene at high levels were not at higher risk of malignant transformation than tissues expressing
p53 protein
at much lower levels. The long latent period and low penetrance suggest that overexpression of
p53
alone is not sufficient to induce malignancies and that additional events are required. These observations provide direct evidence that mutant alleles of the
p53
oncogene have oncogenic potential in vivo and that different cell types show intrinsic differences in susceptibility to malignant transformation by
p53
. Since recent data suggest that
p53
may be a recessive oncogene, it is possible that the elevated tumor incidence results from functional inactivation of endogenous
p53
by overexpression of the mutant transgene. The high incidence of lung and bone tumors suggests that
p53
transgenic mice may provide a useful model to investigate the molecular events that underlie these malignancies in humans.
...
PMID:High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. 247 68
A post-transcriptional control of gene expression was found to be responsible for a down-regulation of
p53 mRNA
accompanying the induced differentiation of murine
erythroleukemia
(MEL) cells. Such a post-transcriptional control was governed by the induced synthesis of an RNA species (inRNA). In an attempt to find a potential candidate for such a function, we have localized the post-transcriptional regulation of
p53 mRNA
in the nuclear compartment of the cells; the various fragments of the
p53
gene were used as probes for induced RNA(s) susceptible to interacting with
p53
pre-mRNA. This experimental approach allowed for the identification of a nuclear RNA molecule, approximately 1.3 kb long, which was recognized specifically by a PstI-HindIII fragment located in the 5' part of the first intervening sequence of the
p53
gene. This RNA accumulated when cell were treated by the inducer concomitantly with high mol.wt
p53 mRNA
precursors. However this RNA was not a maturation product of
p53
pre-mRNA as evidenced by its antisense orientation with respect to this RNA. Moreover it was markedly enriched in the poly(A)+ fraction. The complementary part of inRNA in the
p53
gene has been sequenced over approximately 1200 bp; no extensive homology was found in gene data banks but three restricted areas of the sequence were found homologous to a limited number of genes; they were themselves partially homologous to known repetitive sequences. Possible implication of such a sequence in the regulation of
p53
gene expression is discussed.
...
PMID:An antisense RNA involved in p53 mRNA maturation in murine erythroleukemia cells induced to differentiate. 248 Feb 34
1
2
3
4
5
6
7
8
9
10
Next >>